Neuren Pharmaceuticals (FRA:NK9) Moat Score: 4/10 (As of Jul. 12, 2026)


FRA:NK9 Neuren Pharmaceuticals Ltd FRA:NK9
54 GF Score
Price €9.80
GF Value €4.27
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals Moat Score?

Neuren Pharmaceuticals FRA:NK9 -1.51% 54 Moat Score is 4 as of Jul. 12, 2026. GuruFocus rates FRA:NK9 with a GF Score™ of 54/100 and a GF Value™ of €4.27 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, Neuren Pharmaceuticals ranks better than 88.75% on this metric.

Neuren Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Neuren Pharmaceuticals has Narrow Moat: Neuren Pharmaceuticals Ltd has a discernible but modest moat due to its valuable intellectual property and patents in the pharmaceutical industry. While it faces competition, its R&D capabilities and potential regulatory exclusivity provide some competitive advantage, though not enough for a strong narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Neuren Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Neuren Pharmaceuticals  (FRA:NK9) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Neuren Pharmaceuticals Moat Score Related Terms

FRA:NK9 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Neuren Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuren Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's Moat Score falls into.


FRA:NK9
54GF Score
Neuren Pharmaceuticals Ltd FRA:NK9
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Neuren Pharmaceuticals (FRA:NK9) has a Moat Score of 4 as of Jul. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Neuren Pharmaceuticals ranks #157 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Neuren Pharmaceuticals' Moat Score too high?
Neuren Pharmaceuticals' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Neuren Pharmaceuticals' value of 4 is 100% above this industry median. Based on the distribution chart, Neuren Pharmaceuticals ranks #157 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #157 out of 1396 companies for Moat Score. This places Neuren Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Neuren Pharmaceuticals' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuren Pharmaceuticals's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuren Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (FRA:NK9) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.27, compared to a current price of €9.80 — trading 129.5% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Neuren Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Neuren Pharmaceuticals (FRA:NK9), the current Moat Score is 4 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (FRA:NK9) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of €9.80 is trading 129.5% above its estimated GF Value™ of €4.27. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:NK9:

  • Moat Score: 4
  • GF Value™: €4.27 vs. price of €9.80 (129.5% above fair value)
  • GF Score™: 54/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1396)

No single metric tells the full story. See the FRA:NK9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANEU:Australia
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
54GF Score

Get the complete analysis for FRA:NK9

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.80
Price
€4.27
GF Value